MedTech Dive, Jan 13, 2025: MedTech outlines 5 key issues as MDUFA negotiations restart, including FDA staffing, device safety and effectiveness, and transparency. The article highlights growing concern from NCHR’s Diana Zuckerman and other patient and consumer groups that safety and effectiveness may receive less attention than faster device approvals.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
These are the treatments dominating the business of living longer
Washington Post, January 12, 2026: NCHR is quoted in article about supporters and skeptics about longevity research and resulting products being sold, promoted, and supported by RFK’s HHS but not necessarily approved by FDA.
Read More »Top drug regulator Richard Pazdur set to leave the FDA
STAT reports Pazdur sudden FDA retirement as CDER head as we agree with industry in questioning if FDA can function as a scientific and public health agency when it can’t keep dedicated staff amid controversial decisions on vaccines and other medical products.
Read More »The FDA Commissioner Is Missing the Point of Advisory Committees
MedPage Today, November 22, 2025: Diana Zuckerman’s oped in MedPage Today says FDA was never perfect but the media and public could see how the agency reviewed risks and benefits when they held public meetings where scientists and public citizens debated controversial medical products. In recent months they’ve switched to one-sided rubber stamp meetings followed by announcements of their decisions at events that feel like pep rallies. For example, research shows that hormones for menopause can be helpful or harmful, depending on your age and the type of hormones and your personal medical history. They are not safe for everyone, and can cause cancer, strokes, and dementia for many women. But the FDA expert panel focused on the benefits and ignored most of the risks.
Read More »What the shutdown’s end means for FDA
Politico, November 14, 2025: Politico quotes experts’ questions regarding FDA Commissioner Makary’s plausible mechanism pathway described in NEJM. NCHR Diana Zuckerman doubts insurance would pay for such expensive drugs based on “plausible mechanism” rather than evidence that they are safe and effective.
Read More »